What is Mazdutide?
A dual GLP-1 and glucagon receptor agonist with approvals announced in China for weight management and type 2 diabetes.
Mazdutide in the library · Metabolic & Weight Peptides · Human Trials · What are peptides?
44 registered trials · 10 indexed papers · 23 human / 6 animal studies
From the PeptideWhiz library entry. "As described" sections summarize claims made in the sources; they are not PeptideWhiz endorsements.
What it is
The manufacturer is described as having announced Chinese approvals for weight management and type 2 diabetes in 2025. An approval in one country is described as not making an online research vial an approved prescription product elsewhere.
Overview (as described)
- Main research areas: obesity, overweight with associated conditions, and type 2 diabetes. Human evidence: randomized trials in China and, more recently, the United States.
- Common trial side effects: nausea, vomiting and diarrhea.
Mechanism (as described)
- Two receptor targets in one molecule. GLP-1 signaling is involved in appetite and glucose regulation; the glucagon-receptor component is intended to influence energy metabolism as well.
- That differs from a GLP-1-only drug such as semaglutide and from tirzepatide’s GIP and GLP-1 pairing. Innovent licensed development and commercialization in China from Eli Lilly. Receptor counts are described as not a ranking system.
Registered human trials (44)
Peer-reviewed studies (10)
More cited research
- Efficacy and safety of mazdutide in adults with obesity or overweight: a US-based, multicentre, phase 2, randomised, placebo-controlled clinical trial (2026, human RCT)
- Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: Research Summary (2026, human observational)
- Case Report: Efficacy and safety of dose-escalated Mazdutide, a GLP-1/GCGR dual agonist, in an adolescent with obesity, type 2 diabetes, and hyperuricemia (2025, human case report)
- IBI362 (LY3305677), a weekly-dose GLP-1 and glucagon receptor dual agonist, in Chinese adults with overweight or obesity: A randomised, placebo-controlled, mult (2021, human RCT)
- Mazdutide Ameliorates Metabolic Dysfunction-Associated Steatotic Liver Disease by Modulating Endoplasmic Reticulum Stress, Improving Lipid Metabolism and Allevi (2026, animal)
- The GLP-1R/GCGR Dual Agonist Mazdutide Attenuates Liver Steatosis and Decreases Circulating Cholesterol Levels in Mice With Metabolic Dysfunction-Associated Ste (2026, animal)
- Mazdutide, a dual agonist targeting GLP-1R and GCGR, mitigates diabetes-associated cognitive dysfunction: mechanistic insights from multi-omics analysis (2025, animal)
- Renoprotective effects of tubular glucagon receptor activation mediated by V-ATPase (2026, animal)
Conditions researched
- Atherosclerosis, cardiovascular disease & high blood pressure
- Dementia, Alzheimer's & cognitive decline
- Fat loss, obesity & body recomposition
- Fatty liver & elevated liver enzymes
- Gout
- Heart repair: after heart attack, heart failure & enlarged heart
- Insulin resistance, prediabetes & type 2 diabetes
- Kidney protection (CKD, diabetic kidney, lupus kidney)
- PCOS
- Sleep apnea (obstructive)
- Sleep problems (incl. insomnia on peptides)
Related compounds
- Tirzepatide
- Semaglutide
- Liraglutide
- Exenatide
- Octreotide
- Retatrutide
- ACTH (Corticotropin)
- Angiotensin II
- Endothelin-1
- L-Carnitine
FAQ
What is Mazdutide?
A dual GLP-1 and glucagon receptor agonist with approvals announced in China for weight management and type 2 diabetes.
How many registered human trials study Mazdutide?
The PeptideWhiz trial index lists 44 registered trials for Mazdutide, the most recent from 2026.
How much published research exists on Mazdutide?
The PeptideWhiz paper index links 10 PubMed papers to Mazdutide; by study type, 23 human and 6 animal studies.
Which conditions is Mazdutide researched for?
Atherosclerosis, cardiovascular disease & high blood pressure, Dementia, Alzheimer's & cognitive decline, Fat loss, obesity & body recomposition, Fatty liver & elevated liver enzymes, Gout, Heart repair: after heart attack, heart failure & enlarged heart, Insulin resistance, prediabetes & type 2 diabetes, Kidney protection (CKD, diabetic kidney, lupus kidney), PCOS, Sleep apnea (obstructive), Sleep problems (incl. insomnia on peptides).
Research and education only. Not medical advice. No dosing guidance. Data: ClinicalTrials.gov registry and PubMed via the PeptideWhiz index (204,289 studies).